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ABSTRACT 
Since 1984, when the hypothesis that HIV-causes-AIDS was announced, many scholars have questioned the 
premise and offered alternative explanations. Thirty years later, competing propositions as well as questioning 
of the mainstream hypothesis persist, often supported by prominent scientists.  This article synthesizes the 
most salient questions raised, alongside theories proposing non-viral causes for AIDS. The synthesis is 
organized according to four categories of data believed to support the HIV-AIDS hypothesis: retroviral 
molecular markers; transmission electron microscopy (EM) images of retroviral particles; efficacy of 
antiretroviral drugs; and epidemiological data. Despite three decades of concerted investments in the 
mainstream hypothesis, the lingering questions and challenges synthesized herein offer public health 
professionals an opportunity to reflect on their assumptions and practices regarding HIV/AIDS. 
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AUTHOR’S NOTE OF DISAGREEMENT WITH RETRACTION 
 
“Questioning the HIV-AIDS Hypothesis: 30 Years of Dissent” synthesizes the arguments and evidence 
previously published in the professional/scientific literature, authored by several reputable scholars 
questioning the premise that HIV causes AIDS. The central thesis in this review asserts: “far from being 
condemned to extinction, competing explanations for, and thorough questioning of the mainstream premise 
persist” 30 years after the original HIV-causes-AIDS hypothesis was proposed. 
After conducting a thorough investigation upon the article’s publication in 2014, reviewers and editors alike 
admitted to the review’s “utility … as a historical summary of dissenting theories of AIDS” (Frontiers 
Retraction Statement). Despite this assessment and the concomitant re-classifying of the article as an 
“Opinion”, editors now have concluded their efforts were both “misguided and ineffectual” (Frontiers 
Retraction Statement) and are retracting the article. 
Although the Official Statement from the editors accurately reflects the issues, I respectfully disagree with 
the decision to retract the article for the following reasons: 
(a) The article is a historic review of arguments and data previously published in both scientific 
journals and widely circulated books. In itself, the article lacks the power to constitute a 
“potential public health risk” (Frontiers Retraction Statement), given it is merely presenting 
already-available information. 
(b) Attempts to regulate access to information appear contrary to the spirit driving Open Access 
publishing. 
(c) Debates, grounded in evidence published in the professional/scientific literature, constitute the 
very essence of science and knowledge development. Retraction of information that elicits or 
contributes to such debates represents the antithesis of the scientific method. 
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“The HIV/AIDS hypothesis is one hell of a 
mistake”, wrote Kary Mullis in 1996 (1, p. xiv). 
Mullis—Nobel Laureate in Chemistry, 1993—and 
other distinguished scientists have claimed the HIV-
causes-AIDS hypothesis is false, unproductive, and 
unethical. They have done so since 1984, when the 
hypothesis was proposed. Thirty years after 
countless studies, resources, and attempts to cure 
have been poured into the HIV-AIDS hypothesis, it 
may be fruitful to ask: What happened to those views 
and voices that once disagreed? Have the past three 
decades, with their scientific, technological, and 
public health developments, been sufficient to 
convince critics of the hypothesis’ value? Have these 
advances been able to silence the questioning? 
Here I synthesize the main criticisms aimed 
at the HIV-AIDS hypothesis, alongside select 
unorthodox2 theories proposing non-viral cause(s) 
for AIDS, to argue: far from being condemned to 
extinction, competing explanations for, and thorough 
questioning of the mainstream premise persist. 
Perhaps better known by the lay public than by 
health professionals, many explanations are, in fact, 
attracting a growing number of sympathizers. To 
support the argument, I employ historical research 
and data synthesis methods. I utilize, as data, trade 
and professional publications in tandem with 
authoritative scientific sources.  
It is important to note that my purpose is not 
to review the state of the science regarding HIV/AIDS, 
nor to persuade readers to reject the mainstream 
hypothesis. Instead, I aim to expose readers to the 
persisting controversies, and to motivate them to 
raise questions of their own. Ultimately, then, this 
article invites the public health workforce to reflect 
on prevailing assumptions and practices regarding 
HIV-AIDS. Reflecting on assumptions and practices 
                                                          
2 In this article, I will use the terms unorthodox, non-orthodox, 
non-mainstream and alternative, to refer collectively to those who 
disagree with the prevalent view, and to their propositions (despite 
their variability). I will favor the term “unorthodox” for it carries 
the notion of intention or willful deviation from the norm and 
connotes a power differential in which one set of theories (the 
represents a central task for public health 
professionals; a vital step to ensure their (our) 
practice continually grounds itself in the most 
rigorous ethical standards (3). 
 
HIV causes AIDS: How valid are the data? 
In 1984, Margaret Heckler (then Secretary of 
the Department of Health and Human Services) 
announced a retrovirus was the “probable cause” of 
the alarming immune system collapse emerging in 
the US since 1981(4). When scientists identified 
antibodies to a retrovirus known as LAV, or HTLV-III, 
in 48 persons (from a sample of 119, with and 
without immune deficiency symptoms), the 
retrovirus became the culprit of what would be 
perceived as “the most urgent health problem facing 
the country” in recent history (5, p. 1; 6). 
The announcement intended to assure the 
public: the mystery surrounding this apparently 
contagious and decidedly fatal illness—later labeled 
AIDS for acquired immune deficiency syndrome—
was solved. The newly-identified virus—soon 
renamed HIV, for Human Immunodeficiency Virus—
was, almost certainly, responsible for debilitating 
people’s immune system and making them 
vulnerable to infections which, before AIDS, were 
either rare or not particularly dangerous. Now, 
however, infections such as Kaposi’s Sarcoma and 
Pneumocistis Carinii Pneumonia had morphed into 
vicious killers (4, 7). By identifying the perpetrator, 
scientists’ attention and government resources could 
then focus on treatment, cure, and vaccine 
development. 
Yet almost immediately, scientists who knew 
a great deal about retroviruses and immunology 
began to voice misgivings regarding the HIV-causes-
AIDS hypothesis, and to question it. They highlighted 
the difficulties, flaws, and contradictions they saw in 
orthodox or mainstream) dominates another – what Delborne calls 
“the epistemological tyranny of the intellectual majority” (2,  p. 
510).   
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the hypothesis, and offered alternative explanations. 
Many of the original misgivings have survived, and 
others have been raised, in the past three decades. 
In this paper, therefore, I summarize some of 
these difficulties, and present what critics propose as 
alternative causes of AIDS.  I organize the challenges 
put forth by unorthodox scholars into four categories 
of data that support the HIV-AIDS hypothesis3: (1) 
retroviral molecular markers; (2) transmission 
electron microscopy (EM) images of retroviral 
particles; (3) efficacy of antiretroviral drugs; and (4) 
epidemiological data (8, 9). Because these data are 
proffered as solid evidence for HIV’s role in causing 
AIDS, it is useful to examine how critics question the 
evidence in each category, specifically. 
 
1. Retroviral molecular markers 
Mainstream scientists and physicians claim 
the molecular evidence for HIV-as-the-cause-of-AIDS 
is irrefutable (8, 10) and comprises: (a) HIV antibodies 
and (b) viral load. As incontrovertible as these 
molecular markers appear to be, unorthodox 
scientists have meticulously examined each one and 
detected significant problems in both (9). 
 
(a) HIV antibodies 
The first available tests to screen blood banks 
for HIV detected HIV antibodies (11). Physicians still 
use these tests when screening blood for infection 
and, since 2004, direct-to-consumer home tests have 
become available for identifying antibodies to HIV 
using only a saliva sample (e.g., OraQuick) (12). Yet, 
from the time the first tests appeared, scientists in 
both orthodox and unorthodox camps reiterated 
that, according to established immunology 
principles, antibodies to a virus indicate the immune 
system has acted to control the invading virus. 
Antibodies point to previously-occurring infection 
and do not signal active infection. In 1984, CDC 
scientists (mainstream) wrote,  
“A positive test for most individuals in 
populations at greater risk of acquiring AIDS 
                                                          
3 I am indebted to E. de Harven (9) for suggesting these categories. 
will probably mean that the individual has 
been infected at some time with HTLV-
III/LAV [the names originally used for HIV]. 
Whether the person is currently infected or 
immune is not known, based on the serologic 
test alone” (13, p. 378). 
It is not only this simple argument—
antibodies suggest the immune system has 
controlled the invading agents—that unorthodox 
scientists have debated. The tests themselves remain 
the target of critic’s intense scrutiny. For instance, in 
1996 Johnson reported 60-plus factors capable of 
causing a false-positive result on tests for HIV 
antibodies (either an ELISA or a Western-Blot test) 
(14). Because they react to these factors, the tests 
may not be detecting HIV at all. Worthy of notice, 
among the list, are elements ubiquitous among all 
populations such as the flu, flu vaccinations, 
pregnancy in women who have had more than one 
child, tetanus vaccination, and malaria (an important 
element to consider in the case of the AIDS epidemic 
in Africa). Supporting each factor, Johnson provides 
scientifically valid evidence—published in reputable 
peer-reviewed journals such as AIDS, the Proceedings 
of the National Academy of Sciences of the United 
States of America, The Lancet, the Canadian Medical 
Association Journal, and the Journal of the American 
Medical Association (JAMA) (14).  
Celia Farber’s book, Serious Adverse Events: 
An Uncensored History of AIDS (15)—an exposé of 
the epidemic’s ethically-questionable history—
contains an interesting appendix authored by Rodney 
Richards. Richards—who helped develop the first 
ELISA test for HIV—outlines the “evolution” of CDC’s 
stances regarding the role of antibodies, infection, 
and HIV tests. First, the CDC aligned itself with the 
traditional view of antibodies signaling past/prior 
infection (as evidenced in the quote above, from 
1984). In 1986, the CDC moved toward a qualified 
claim, stating:  
“… patients with repeatedly reactive 
screening tests for HTLV-III/LAV antibody … 
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in whom antibody is also identified by the 
use of supplemental tests (e.g., Western blot, 
immunofluorescence assay) should be 
considered both infected and infective” (16, 
p. 334).  
Finally, in 1987, CDC adopted a nonqualified claim 
that antibodies signify active infection and/or illness: 
“The presence of antibody indicates current 
infection, though many infected persons may have 
minimal or no clinical evidence of disease for years” 
(17; 18, p. 509). 
A more specific measure than the ELISA test, 
the Western Blot (WB) detects antibodies by 
identifying proteins believed to be associated with 
HIV, and only with HIV. A person undergoes a 
confirmatory WB after a prior ELISA screening test 
reacts positively (but it is important to remember: 
over 60 conditions can yield a false-positive ELISA (14, 
19).  
Critics of the orthodox view decry the lack of 
standardized criteria for a positive result in a WB, 
across countries, world-wide (20). Bauer (Table 1), in 
a 2010 article titled “HIV tests are not HIV tests” 
claims, “no fewer than five different criteria have 
been used by different groups in the United States” 
(19, p.7). Moreover—adds Bauer—included in the 
contemporary criteria for a positive WB are p41 and 
p24, protein-antigens “found in blood platelets of 
healthy individuals”. This means: some of the 
biological markers being used to “flag” the presence 
of HIV are not “specific to HIV or AIDS patients [and] 
p24 and p41 are not even specific to illness”. In other 
words, healthy persons may test positive on a WB but 
not carry HIV at all (19, p. 6). 
An example may clarify: If tested in Africa, a 
WB showing reactivity to any two of the proteins 
p160, p120, or p41, would be considered positive for 
HIV. In Britain, the test would be positive only if it 
showed reactivity to one of these three proteins, 
together with reactions to two other proteins, p32 
and p24 (see mention of p24, above, as occurring in 
healthy individuals). Therefore, someone whose test 
reacts to p160 and p120 would be considered HIV-
positive in Africa, but not in Britain. A test reaction to 
p41, p32 and p24 would be considered positive in 
Britain, but negative in Africa, leading author Celia 
Farber to comment: “… a person could revert to 
being HIV-negative simply by buying a plane ticket 
from Uganda to Australia [or in our example, from 
Uganda to London” (15, p. 163)].  
According to critics, a definitive answer 
regarding which protein-antigens are specific to HIV 
and HIV alone, can only come from successful virus 
isolation and purification. Isolating and purifying 
“would be required to verify that all of these proteins 
actually originate from HIV particles” (9, p. 70). 
Attempts at purifying have been made (21, 22), but 
have been criticized for their ambiguous findings 
(23), or for their use of cultured samples (see 
discussion below on EM images). To date, the issue 
of HIV isolation in purified samples has not been 
addressed to critics’ satisfaction (24). 
 
(b) Viral load 
The expression “viral load” refers to the 
quantity of virus found in HIV-infected blood. 
According to the mainstream perspective, 
information on viral load helps monitor the 
infection’s progress, “decide when to start 
treatment, and determine whether or not … HIV 
medications are working” (25). 
The technique for measuring viral load is 
known as RNA PCR—ribonucleic acid polymerase 
chain reaction (26). Mainstream scientists regard this 
test as the most specific documentation of HIV’s 
presence in a person’s body. It is often used when the 
ELISA and WB tests are negative, because PCR can 
detect the virus’ genetic material (or its RNA/DNA 
fragments), before the human body has had a chance 
to recognize the virus, produce antibodies in defense, 
and react positively in an antibodies-only test (27). 
Despite its enhanced specificity, many 
mainstream scientists and practitioners recommend 
caution when using PCR for screening or diagnosing 
infection (28). For instance, authors of a study 
published in JAMA in 2006, in which PCR was used 
with a sample of almost 3,000 people, concluded: 
  
 
 
 
UNPUBLISHED MANUSCRIPT, OCTOBER 2019 
COPYRIGHT © 2014 GOODSON 
_________________________________ 
Page | 6  
 
“The PCR assay is not sufficiently accurate to be used 
for the diagnosis of HIV infection without 
confirmation” (29, p. 803). 
PCR technology evolved quickly since it was 
introduced in 1983 (26). Although being employed, 
mostly, for assessing viral load (less for screening and 
diagnosis), it should give us pause to learn, however, 
that Dr. Kary Mullis—the scientist who won the 1993 
Nobel Prize for inventing the PCR test and whose 
quote introduced this article (Table 1)—has strongly 
opposed using the technique for determining the 
amount of virus circulating in plasma. Lauritsen 
explains: 
“Kary Mullis … is thoroughly convinced that 
HIV is not the cause of AIDS. With regard to 
the viral load tests, which attempt to use PCR 
for counting viruses, Mullis has stated: 
“Quantitative PCR is an oxymoron.”  PCR is 
intended to identify substances qualitatively, 
but by its very nature is unsuited for 
estimating numbers. Although there is a 
common misimpression that the viral load 
tests actually count the number of viruses in 
the blood, these tests cannot detect free, 
infectious viruses at all; they can only detect 
proteins that are believed, in some cases 
wrongly, to be unique to HIV. The tests can 
detect genetic sequences of viruses, but not 
viruses themselves” (30, p. 3).  
If to this picture we add human endogenous 
retroviruses (or HERVs) (31) as potential 
confounders, the genetic sequences detected in a 
PCR test may not be those from an exogenous virus, 
at all, and may explain the test’s substantial false-
positive rates (19, 28). HERVs consist of retrovirus-
like particles produced by host cells that are stressed 
or dying. In other words, when various infections 
assail the body, and certain cells experience stress or 
die in large numbers, they can manufacture by-
products similar to retroviruses. These by-products 
can be reactive when testing for HIV antibodies, 
protein antigens and viral loads (32). Culshaw 
summarizes it well: 
“A retrovirus is nothing more than RNA with 
an outer protein shell. The shell enables it to 
bind to cells of the type it infects, and once it 
gains entry, the outer coating disappears and 
the RNA is transcribed to DNA and 
incorporated as provirus into the host cell’s 
own genome. It is for this reason that 
retroviruses are called enveloped viruses, 
and it is also the reason that it is very difficult 
to distinguish between exogenous 
retroviruses (those that originate outside the 
body from a foreign invader) and 
endogenous retroviruses (those that are 
manufactured from our own retroviral-like 
genetic sequences under conditions of 
cellular stress, including diseases) … Much of 
the genetic material attributed to HIV is in 
fact DNA or RNA from [these] decaying cells 
(…) Human beings are filled with such 
endogenous retroviruses” (33, pp. 53, 55-
56). 
 
2. Transmission electron microscopy (EM) images of 
retroviral particles  
Although it seems intuitive that 
photographing HIV would provide undeniable 
evidence of its presence in the host’s plasma, the 
reality is much more complex. Adequately 
interpreting images obtained through electron 
microscopy (EM) is, even for the most skilled 
scientists, challenging. Electron microscopy (EM) 
generates highly amplified images of cells and viral 
particles. An electron microscope uses “beams of 
electrons focused by magnetic lenses instead of rays 
of light” to produce images magnified up to 
10,000,000x (a light microscope has difficulty 
exceeding 2000x magnification) (34). 
The first images of what researchers believed 
to be HIV particles budding out of human cells were 
published in the journal Science, in 1983, by the 
French team that co-discovered HIV (headed by Luc 
A. Montagnier) (35). These images, and the computer 
graphics based on them, were printed in textbooks 
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and articles discussing AIDS, extensively. Despite 
their popularity, the images were obtained from a 
“pre-AIDS” patient (not a patient with AIDS), and the 
sample furnishing the images had not been purified 
according to standard procedures (36).  
It would be fourteen years later, in 1997, 
when EM images from purified samples were 
produced (21). Yet another study (23), published 
simultaneously with these images (in fact, printed as 
an adjoining article), reported: even purified HIV 
samples harbor protein particles (called 
microvesicles), considered to be contaminants. 
These microvesicles do not disappear during the 
purifying process. In other words, even when 
technicians purify HIV samples, certain “cellular 
proteins bound to nonviral particles (i.e., 
microvesicles) can copurify with [the] virus”, and 
appear in the EM images. The question, then, 
remains: are the EM images seen in these purified 
samples, pictures of HIV itself, or of other 
elements/particles? (37). 
In 2010, Ettiene de Harven—the scientist 
who “produced the first electron micrograph of a 
retrovirus (the Friend leukemia virus)” (33, p.13) 
through electron microscopy research in 1960 (Table 
1) (38)—added to the debate: 
“All the images of particles supposedly 
representing HIV and published in scientific 
as well as in lay publications derive from EM 
studies of cell cultures. They never show HIV 
particles coming directly from an AIDS 
patient” (9, p. 70—emphasis added). 
 
Why is it important to obtain EM images of 
HIV from AIDS patients, as opposed to images of HIV 
cultured in a laboratory? According to de Harven, 
non-viral micoorganisms frequently contaminate cell 
cultures and show up very easily in EM. It is quite 
difficult to obtain absolutely pure cell cultures, 
especially because the culturing process itself—the 
growth factors added to the culture, such as “T cell 
lymphocyte growth factor (TCGF), or interleukin2, or 
corticosteroid hormones” (24, p. 4)—can introduce 
potential contaminants. HERVs, for example, are 
often generated by cells that have been stressed or 
hyperstimulated to grow in cultures. HIV cultures 
obtained from patients with AIDS may not require as 
much stimulation or addition of growth factors, thus 
resulting in less contaminated, purer cultures.  
Montagnier also acknowledges the problems 
with relying on EM to identify a retrovirus, given the 
difficulties with purifying viral samples. In an 
interview given in 1997, he reflects on those first HIV 
images from cultured samples, produced in his 
laboratory at the Pasteur Institute: 
“DT (Djamel Tahi) :  Why do the EM 
photographs published by you, come from 
the culture and not from the purification? 
LM (Luc Montagnier): There was so little 
production of virus it was impossible to see 
what might be in a concentrate of virus from 
a gradient. There was not enough virus to do 
that … 
(…) 
DT: How is it possible without EM pictures 
from the purification, to know whether these 
particles are viral and appertain to a 
retrovirus, moreover a specific retrovirus? 
LM: Well, there were the pictures of the 
budding. We published images of budding 
which are characteristic of retroviruses. 
Having said that, on the morphology alone 
one could not say it was truly a retrovirus …” 
(39). 
 
It appears, therefore, there is little consensus 
regarding what the existing EM images reflect: are 
the visualized particles HIV or something else? 
According to Papadopulos-Eleopulos and colleagues, 
“some of the best known retrovirologists including 
Peter Duesberg, Robert Gallo and Howard Temin 
have been telling us that particles may have the 
morphological characteristics of retroviruses but are 
not viruses” (40, p. 2). It is feasible, therefore, that 
EM images are, in fact, depictions of (a) microvesicles 
(or protein particles), not viral or infectious in nature, 
but not eliminated even when using purified samples 
(23); or (b) human endogenous retroviruses—
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defective, non-infectious retroviruses associated 
with the host’s own genome (see discussion above on 
HERVS).  
 
3. Efficacy of antiretroviral (ARV) drugs 
From the epidemic’s onset, researchers 
worked relentlessly to find a vaccine to keep the virus 
from spreading, and to develop drugs for managing 
the symptoms from opportunistic infections (41). The 
challenges inherent in developing both vaccine and 
treatment were daunting: Post-infection, HIV 
appears to mutate and recombine continually, thus 
making it difficult to design an effective vaccine (42, 
43). Furthermore, designing treatments for a 
retrovirus is a tricky feat, given it shares many of the 
same characteristics of the host’s immune cells—
thus, an attack on the virus can become a 
simultaneous attack on the healthy host cells (15, 33, 
36). 
After the public announcement regarding 
the probable cause of AIDS, various pharmaceutical 
companies tried to develop drugs to thwart the 
action of the virus’ reverse transcriptase enzyme (an 
enzyme essential for the replication of retroviruses). 
AZT became the first medication of this kind, 
approved specifically for treating AIDS patients in 
1987 (44). Azidothymidine (AZT)—also known as 
Retrovir, a drug originally designed, but proven 
unsuccessful, for treating leukemia—made history 
not only because it was the first available treatment 
specifically for AIDS, but also due to how quickly it 
was approved: AZT received “Investigational New 
Drug (IND) status (initial approval for testing) within 
five days of application” (45, p. 134). Given the 
desperate need for specific treatment, the drug’s 
placebo-controlled trials also moved fast, lasting 
“only six months before approval was given for 
general sale” (45, p. 134). Phase II trials were 
interrupted, mid-way, due to findings that fewer 
patients taking AZT were dying of AIDS when 
compared to the control group not taking the drug 
(45,46). 
Approving AZT, however, did not prevent 
scientists from trying to develop other drugs, during 
the following decade; but most attempts would make 
little headway into the treatment of AIDS. Adding to 
these difficulties, AZT was proving to be extremely 
toxic and not as effective as initially anticipated. 
Researchers did learn, meanwhile, that prescribing 
AZT in lower dosages and in combination with other, 
well-known drugs such as heparin, acyclovir, and 
Bactrim, was beginning to curb mortality rates (45). 
Thus, in the mid-90s “combination therapy” 
became available. Also referred to as the “drug 
cocktail”, combination therapy comprised a joint 
attack on HIV using three main classes of drugs, 
simultaneously: (a) those inhibiting reverse 
transcriptase’s ability to duplicate the virus’ genetic 
material using host DNA sub-divided into two classes 
– nucleoside and nonnucleoside inhibitors;  (b) 
protease inhibitors (designed to limit certain proteins 
needed for HIV assembly); and (c) myristoylation or 
entry/fusion inhibitors (blocking the virus from 
entering the host cells). These three classes of 
drugs—known collectively as HAART (highly active 
antiretroviral therapy) or ARVs (antiretrovirals)—
have been praised for their ability to restore the 
health of patients with AIDS who become extremely 
ill (25; 45, p.240; 47).  
ARVs also are praised for their ability to 
reduce patients’ viral loads and, therefore, their level 
of infection and ability to transmit the virus (or 
infectivity). This reduction in viral load has been 
deemed so significant that, in 2012, the FDA 
approved using one of the combination drugs 
(Truvada) for pre-exposure prophylaxis or PrEP (48).   
PrEP or “HIV treatment-as-prevention” (49) 
involves administering to non-infected persons one 
pill of the antiretroviral, daily, to stave off infection: 
an initiative crowned Breakthrough of the Year by the 
journal Science, in 2011(48). Trials conducted world-
wide have consistently demonstrated low rates of 
HIV infection among people taking PrEP (42, 49). The 
2011 breakthrough, therefore, was the conclusion: 
“The early initiation of antiretroviral therapy reduced 
rates of sexual transmission of HIV-1 and clinical 
events, indicating both personal and public health 
benefits from such therapy” (42, p. 493).  
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Yet, as with most treatment drugs, ARVs also 
produce important side-effects. Even mainstream 
scientists who praise the drugs by saying, 
“Combination theory [sic] was a miracle, comparable 
with antibiotics, anesthesia, and the polio vaccine in 
the annals of the history of medicine … a ‘quantum 
leap’”—candidly admit: “The miracle was not 
without complications...” (45, pp. 246, 247). Because 
these drugs also attack non-infected cells, they can 
destroy the immune systems’ healthy T-cells, and 
even cause a collapse identical to AIDS. Authors of a 
study reporting on the first decade of ARV use 
concluded,   
“The results of this collaborative study, which 
involved 12 prospective cohorts and over 
20,000 patients with HIV-1 from Europe and 
North America, show that the virological 
response after starting HAART has improved 
steadily since 1996. However, there was no 
corresponding decrease in the rates of AIDS, 
or death, up to 1 year of follow-up. 
Conversely, there was some evidence for an 
increase in the rate of AIDS in the most recent 
period [2002-2003]” (50, p. 454 – emphasis 
mine). 
Critics’ concerns center on the potential 
association between use of HAART and a depressed 
immune system. This association carries significant 
implications for the prophylactic use of ARVs. For 
instance, studies have documented patients’ 
compromised immune systems as preceding their 
seroconversion (51, 52). Therefore, having non-
infected persons take HAART as prophylaxis may, 
over time, impact their immune systems negatively, 
and predispose them to becoming infected with 
various agents, including HIV itself. Moreover, there 
is evidence that ARVs can accelerate aging of cells in 
ways that promote progressive multi-organ disease 
(53). Critics also point to data on patients taking ARVs 
who develop Pneumocystis Carinii, and Candida 
Albicans (opportunistic infections typical of patients 
with AIDS) while on the drugs, despite the fact the 
protease inhibitors have “marked anticandidal and 
antipneumocystis effects” (9, p. 71). Equally vexing, 
are the deaths among ARV-treated patients, resulting 
from acute liver failure. These deaths point to the 
ARVs’ detrimental effects, given that HIV, itself, does 
not cause liver toxicity (9, 54, 55). 
Critics also highlight studies documenting the 
reduction of plasma HIV RNA among patients treated 
with ARVs, but the non-reduction in HIV DNA, 
suggesting there is “continued expression of viral 
agents” even after one year of treatment (56, p. 320). 
Compounding these difficulties are the often 
debilitating side effects (46), the drugs’ extremely 
high costs (AZT alone cost around $6,000 a year and 
the cocktails can easily tally $12,000 – 13,000 a year 
per patient) (45, pp. 245-246) and the oftentimes 
daunting regimen some prescriptions require, 
leading to patients’ less-than-optimal compliance 
during treatment.  
Despite this host of problems, orthodox 
scientists and practitioners still claim HAART has 
changed the face of the AIDS epidemic: once 
considered a lethal syndrome, testing positive for HIV 
does not equate to a death sentence any longer; 
merely to a lifetime of managing a chronic infection 
(6, 57). Critics, on the other hand, assert: because the 
drugs are anti-viral and anti-bacterial in nature, they 
give a false impression of being effective for treating 
HIV infection. What appears a miraculous recovery in 
many patients is, in fact, the drugs’ effects upon the 
opportunistic infectious agents the person may 
harbor at the time, other than HIV. Contrary to the 
reigning enthusiasm for ARVs’ effectiveness for 
prevention and treatment, critics will argue the risks 
associated with ARVs appear to outweigh the 
benefits, especially if these drugs are consumed over 
long periods of time. In short, unorthodox scholars 
believe the appearance of effectiveness of ARVs does 
not represent strong evidence for the role of HIV in 
AIDS and, in a paradoxical manner, ARVs may actually 
be the cause of AIDS-defining illnesses and non-AIDS-
defining ones.  
 
4. Epidemiological data 
It is easy to obtain current statistics 
describing the HIV-AIDS distribution, world-wide. 
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One has only to access the website of the Joint United 
Nations Programme on HIV to learn: “In 2012 there 
were 35.3 million [32.2 million-38.8 million] people 
living with HIV” and that, in the same year, “1.6 
million [1.4 million-1.9 million] people died from 
AIDS-related causes worldwide compared to 2.3 
million [2.1 million-2.6 million] in 2005” (58). 
Scholars on both sides of the debate agree: 
“epidemiologic studies and data can show only that a 
risk factor is statistically associated (correlated) with 
a higher disease incidence in the population exposed 
to that risk factor” (59, p. 42). Epidemiological data 
do not provide evidence for causation. All the data 
can do is reveal risk factors and illness co-occurring in 
a given group. Despite this well-known caveat, 
mainstream scientists argue that because HIV has 
spread among high-risk groups as expected, the AIDS 
epidemic has, indeed, a viral, infectious agent: its 
“epidemic curves resemble … such infectious agents 
as hepatitis B and genital herpes viruses” (59, p. 53). 
These scientists also will explain the differences 
observed in the frequency of certain illness in specific 
geographic regions (e.g., higher numbers of HIV-
related Tuberculosis in sub-Saharan Africa) as caused 
by the “background flora of infectious disease 
agents” present in these regions (59, p. 54).  
Curiously, however, even among mainstream 
scholars who believe epidemiological data constitute 
valuable evidence of a viral cause for AIDS, there are 
those who have turned a critical eye toward the data 
the US and the WHO have compiled. James Chin—
one such critic (Table 1) writes in his book, The AIDS 
Pandemic: The Collision of Epidemiology with Political 
Correctness: 
“Estimation and projection of HIV infections 
and AIDS cases and deaths (HIV/AIDS) can be 
considered more of an art than a science 
because of the marked limitations of both 
available data and methods for estimation 
and projection. These limitations make it 
possible for UNAIDS and other AIDS program 
advocates and activists to issue misleading 
and inflated estimates and projections” (59, 
p. 137).  
The questions regarding the validity and 
reliability of epidemiological data emerging from 
within the mainstream/orthodox views have been 
echoed and amplified by unorthodox scholars. Both 
camps’ concerns center on four problems plaguing 
the estimates of incidence (new cases), prevalence 
(remaining cases), and projection (future cases) of 
HIV infections, AIDS diagnoses, and AIDS-related 
deaths: (a) the varying clinical definitions of AIDS (the 
official definition has changed four times since 1982) 
(60); (b) variability in the criteria for seropositivity in 
HIV tests; (c) the absence of testing in many regions 
of the world (many developing countries do not have 
the laboratories needed to test every single AIDS case 
); and (d) the mistakes in estimation, data 
management and reporting (e.g., the revision of 
projections for year 2006 by UNAIDS) (59-62). 
This article’s space limitations do not allow 
an expanded treatment of each problem-area, but 
readers can find further details within the works 
cited. For instance, in Rebecca Culshaw’s book—
Science Sold Out: Does HIV Really Cause AIDS (33)—
readers will find 13  “failed predictions” regarding the 
spread of HIV and AIDS, including the prediction that 
HIV infection would spread randomly among 
populations (i.e., outside specific risk groups). 
Culshaw also tells her personal story of having 
written a master’s thesis, received a Ph.D. based on 
her work with “mathematical models of the 
immunological aspects of HIV infection”, and 
eventually concluding “there is good evidence that 
the entire basis for this theory is wrong” (33, p.7).  
 
Unorthodox theories: If not HIV, then what? 
If the criticisms outlined above pinpoint 
significant problems with each type of data used to 
support the HIV-AIDS hypothesis, they only 
contribute to deconstructing the hypothesis, not to 
providing explanations for what might cause AIDS if 
not a retrovirus. Alternative hypotheses abound, 
however. Anchoring themselves in well-established 
causes of immune system malfunction, these 
hypotheses point to pharmacological (drug) factors, 
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immune dis-balance factors, latent infection 
overload, and malnutrition as culprits.  
Although several scientists investigated the 
role drugs might play in causing immune suppression 
before HIV was identified (see a list of these studies 
in Duesberg et al., 2003 [47]), the main proponent of 
the drug-AIDS hypothesis in the epidemic’s early 
years was Peter Duesberg, a professor of Molecular 
and Cell Biology at UC Berkeley. According to Seth 
Kalichman, who wrote Denying AIDS (a harsh critique 
of unorthodox views and of Duesberg in particular), 
“In every respect, HIV/AIDS denialism starts and ends 
with Peter Duesberg” (63, p. 175). Duesberg’s 
arguments gained notoriety among unorthodox 
theories not only due to his expertise and 
prominence (see Table 1), but also to his challenge of 
the medical and scientific establishments early in the 
history of the epidemic, employing clear empirical 
logic.   
Duesberg began challenging the viral 
hypothesis for AIDS soon after the publication (in 
1984) of the four seminal articles pointing to HIV as 
the “probable” cause (64-67). In two key publications 
in 1987 and 1989—in Cancer Research and in the 
Proceedings of the National Academy of Sciences (68, 
69)—Duesberg cogently argued: retroviruses are not 
known for killing cells. In other words, retroviruses 
are not “cytocidal”. If anything, retroviruses were 
once thought to be associated with cancer because 
they cause precisely the opposite of cell death; they 
contribute to cells’ growth or proliferation. In 
Duesberg’s words, “… retroviruses are … considered 
to be plausible natural carcinogens because they are 
not cytocidal and hence compatible with neoplastic 
growth and other slow diseases.” (68, p. 1200). In his 
view, HIV’s inability to kill cells could not explain the 
suppression of the T-cells in the immune system, as 
proposed by the teams who discovered HIV4. 
According to Farber,  
“In other fields, such as gene therapy, it is 
axiomatic that retroviruses are the ideal 
                                                          
4 In fact, evidence supporting the notion “HIV kills T-cells” has 
been so conspicuously absent that, currently, scientists don’t 
carriers for genetic materials, because they 
‘don’t kill cells’. Incredibly, this is where the 
so-called HIV debate first forked in 1987, and 
where the camps remain bitterly divided to 
this day” (15, p. 50). 
 
For Duesberg and scientists agreeing with 
him, then, other agents would have to be responsible 
for the disastrous immune function collapse seen in 
AIDS patients. These scientists saw as prominent 
among such causes, the use of drugs, both 
recreational and routinely prescribed ones. As author 
Gary Null points out, even before AIDS, researchers 
were documenting the immune-suppressing effects 
of amyl nitrites or “poppers” (the form of amyl 
nitrites popular among gay men in the early and mid-
80’s) and determining both their toxicity and 
carcinogenic properties in humans and animals (46). 
However, two studies CDC published in 1983, one in 
which they were unable to detect any toxicity from 
amyl nitrites, the other, unable to document a 
significant association between inhaled nitrates and 
Kaposi’s sarcoma or Pneumocystis carinii pneumonia, 
led the search to a halt (70, 71). Investigators later 
tried to determine if certain batches might have been 
contaminated with toxic agents but, when they found 
no contamination, the focus on poppers/amyl nitrites 
themselves ceased (1). Nonetheless, in 1998 
Duesberg and Rasnick (Table 1) (72) reviewed 
evidence published since 1909, “which prove[s] that 
regular consumption of illicit recreational drugs 
causes all AIDS-defining and additional drug-specific 
diseases at time and dose-dependent rates” (47, p. 
393). 
Other drugs such as those given to transplant 
patients to prevent organ rejection, as well as 
routinely-prescribed antibiotics, also have been 
implicated as potential causes of immune 
dysfunction. Studies have shown that transplant 
patients who develop Kaposi’s sarcoma will go into 
remission, once taken off the drugs required to avoid 
believe HIV “kills T-cells in any way. Rather, they believe HIV 
primes T-cells to commit suicide at some later time” (33, p. 73). 
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organ rejection. Immune suppressing drugs (as well 
as amyl nitrites) have, for instance, been directly 
correlated with Kaposi’s sarcoma, the rare skin 
cancer found frequently among AIDS patients during 
the epidemics’ early days (see reviews by Null, 2002 
[46]  and Kremer, 2008 [36]).   
Antiretroviral drugs used to treat HIV 
infection/disease, also, are indicted by Duesberg and 
those who agree with him as potentially causing AIDS 
(44, 62).  Because the drug cocktails include “DNA 
chain-terminators and protease inhibitors” that 
affect healthy cells as well as the virus, and because 
“many studies find that people receiving 
antiretroviral medications experience AIDS-defining 
diseases to a greater extent than controls not 
receiving those medications” (73, p. 122), 
antiretrovirals are viewed as potential immune 
suppressors. 
In a review of the chemical bases for AIDS, 
published in 2003, Duesberg and his colleagues (47) 
outlined the epidemiological and bio-chemical 
evidence supporting different causes for the AIDS 
epidemics in the US/Europe and in Africa, none of 
which are viral or contagious. The authors concluded: 
“The chemical-AIDS hypothesis proposes 
that the AIDS epidemics of the US and Europe 
are caused by recreational drugs, alias 
lifestyle, and anti-HIV drugs … and by other 
non-contagious risk factors such as 
immunosuppressive proteins associated with 
transfusions of blood clotting factors … 
pediatric AIDS is due to prenatal 
consumption of recreational and anti-HIV 
drugs by unborn babies together with their 
pregnant mothers … The chemical basis of 
African AIDS is proposed to be malnutrition 
and lack of drinkable water … exactly as 
proposed originally by the now leading HIV-
AIDS researchers Fauci and Seligman: “The 
commonest cause of Tcell immunodeficiency 
worldwide is protein-calorie malnutrition” … 
and others …” (47, p. 392). 
 
Alongside a drug hypothesis, another 
proposed cause for AIDS is the iNOS hypothesis, or 
immune dis-balance hypothesis. In his book, The 
Silent Revolution in Cancer and AIDS Medicine, 
Kremer (2008) (36) (Table 1) explains that much of 
what scientists now know about the immune system 
and its functions was not well understood at the time 
they identified HIV. In particular, the research on NO, 
or nitric oxide, was still in its infancy: NO is “an 
important intracellular and intercellular signaling 
molecule” acting as “…an important host defense 
effector in the immune system” (74, p. 639). Even 
though NO (and its derivative iNOs) is “involved in the 
regulation of diverse physiological and 
pathophysiological mechanisms in cardiovascular, 
nervous and immunological systems”, researchers 
have shown it can also become a harmful, “cytotoxic 
agent in pathological processes, particularly in 
inflammatory disorders” (74, pp. 639-640). Put 
simply, at adequate levels NO helps regulate blood 
pressure as well as “wound repair and host defence 
[sic] mechanisms” (75, p. 277). Excessive amounts, 
however, lead to T-cell depletion, “inflammation, 
infection, neoplastic diseases [cancer], liver cirrhosis 
[and] diabetes” (75, p. 277). This change from 
adequate-to-excessive amounts of NO in the human 
body results from multiple factors, including “nitrite 
inhalation [e.g, using ‘poppers’], microbial antigen 
and toxin stimulation [e.g., suffering repeated 
infections with different viruses/bacteria], 
immunotoxic medications [e.g., taking ARVs and 
antibiotics], [and] many other stress factors” (36, p. 
49).  
A closely related perspective, placing the 
blame for AIDS on biochemical processes gone awry 
within human cells is the oxidative stress (or redox) 
hypothesis. Oxidative stress is a cellular-level electro-
chemical phenomenon that diminishes a cell’s ability 
to absorb oxygen. This diminished capacity to process 
oxygen at optimal levels leads to the cell’s disruption 
and death. Scientists have either hypothesized or 
empirically connected oxidative stress to many 
diseases, including type 2 diabetes and cancer (36, 
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46, 76). According to this hypothesis’ main 
proponents,  
“At first sight it appears that there is no 
common factor, apart from HIV infection, 
linking the various AIDS risk groups. 
However, homosexuals are exposed to 
relatively high levels of nitrites and anally 
deposited sperm, drug abusers to opiates 
and nitrites, hemophiliacs to factor VIII. All 
these are known potent oxidizing agents …” 
(77, p. 147 – emphasis mine). 
For these proponents of the redox hypothesis even 
Luc Montagnier (the head of the French team that 
discovered HIV) agrees “that anti-oxidants should be 
used for treatment of HIV/AIDS patients” (78; 79, p. 
6).  
Viewing a person’s immune system as a 
complex dynamic balancing act among various 
elements, which sometimes behave as defenders, 
other times, as offenders, is also consistent with the 
“latent infection overload hypothesis” proposed by 
Kary Mullis (Table 1). According to Mullis, as people 
become infected with multiple viruses and 
experience many latent infections, the immune 
system embarks on a chain-reaction-response to 
each virus. Latent infections are those without visible 
symptoms, and according to Mullis, “at a given time 
most viral infections in an individual are latent” (80, 
p. 196). Eventually, the system overloads itself and 
becomes dysfunctional. AIDS, he says, “may be the 
result of such a chain reaction”. This hypothesis 
assumes: 
“… there is not a single organism that is the 
cause of AIDS, and there should exist AIDS 
patients who do not test positive for HIV5. It 
is an overwhelming number of distinct 
organisms which causes the immune 
                                                          
5 Some would argue this is the strongest evidence against the HIV-
AIDS hypothesis: cases of AIDS with no documentable presence 
of HIV. However, say the critics, the difficulty with this argument 
lies in the definition of AIDS: because AIDS is defined as “the 
final stage of HIV infection” (81), AIDS presupposes infection with 
HIV, making the definition a circular one (i.e., AIDS = final stage 
dysfunction. These may individually be 
harmless” (80, p. 197).  
 
Perhaps the most intriguing alternative 
hypothesis, however—if not from its biochemical 
perspective, at least from the perspective of who 
supports it—is the one proposing HIV may not be the 
primary villain, but merely an accomplice in causing 
AIDS (83). Joseph Sonnabend—a prominent 
physician/researcher responsible for encouraging his 
gay patients to lead a healthy lifestyle to avoid 
developing AIDS, and one who “did not accept 
HIV=ADS theory for many years”—recently changed 
his views and “has come to think that HIV, together 
with other factors, may play a subsidiary causative 
role” (73, p. 120; 84). Even Montagnier and Gallo 
(leaders of the French and American teams, 
respectively, that discovered HIV), at various times 
since the epidemic began, have suggested HIV might 
be a co-factor in AIDS, not its exclusive causative 
agent (85).   
Other hypotheses have been proposed over 
the years, but none have garnered as much attention 
as those outlined above. Some of these other 
hypotheses claim AIDS is caused by (a) multiple 
factors; some factors explaining some cases, other 
factors accounting for other cases; (b) undiagnosed 
or untreated syphilis infection; (c) autoimmunity; (d) 
selenium deficiency, and (e) psychological factors, 
including stress and trauma (see Bauer 2007[73, pp. 
124, 136-139] for details on these hypotheses).  
The positive or reassuring aspect of these 
alternative hypotheses is the tangible hope for 
prevention, treatment and cure they embody. 
Nevertheless, it is difficult not to agree with Bauer 
when he concludes, “…it is hardly reassuring that this 
array of suggestions has been in circulation for 
of HIV infection = opportunistic infections + high viral load + 
low CD4 counts).  Due to the circularity in the logic, if there is no 
HIV, there can be no AIDS. Nonetheless, cases of patients with 
AIDS-defining opportunistic infections and low CD4 counts 
without HIV do exist (see, for example, the review by Green and 
colleagues (82). 
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something like [three] decades without having been 
adequately explored” (73, p. 139).  
 
Discussion 
At this point, readers might be wondering: 
Given the problems with the mainstream hypothesis, 
how did we get here? How did we come so far, 
tethered to such a problematic perspective?  The 
complexity of the answers to these questions aside, 
it may help to bear in mind the notion that HIV causes 
AIDS emerged and developed within a very specific 
scientific-cultural-historic context. Although the 
scope of this article precludes dealing with this 
complex context, for our purposes it is important to 
recall at least one element:  Funding for President 
Nixon’s War on Cancer campaign ended in 1981 with 
very little achieved in the quest for an infectious 
cancer agent (16, 85-87). The only exception was the 
discovery connecting select retroviruses to a few, 
rare cancers. Other than this, scientists had a handful 
of “orphaned” viruses which, they suspected, might 
play a role in causing illnesses, but no known diseases 
to which these viruses could be connected. Proposing 
a connection between an emerging syndrome and 
one of these viruses (even if only a circumstantial 
connection) proved enticing enough to pursue. And 
pursue they did, as soon as AIDS began to appear in 
larger-than-expected numbers among otherwise 
healthy adults.  
If viewed from this perspective, then, why 
scientists so quickly and assuredly “jumped on the 
HIV bandwagon” may not be very difficult to 
understand. That the scientific establishment world-
wide insistently refuses to re-examine the HIV-AIDS 
hypothesis, however, is more difficult to accept, 
especially when one examines the credentials of 
those proposing such a revision.  Their expertise 
carries as much weight as the teams who defend the 
orthodox hypothesis (Table 1). Seth Kalichman, a 
critic of AIDS “denialists”, recommends adamantly: 
anyone who entertains alternative views should 
“consider the source: credibility of where the article 
is reported as well as the researchers themselves 
must be weighed” (63, p. 159). I couldn’t agree more: 
taking into account the credibility of the scholars who 
question the HIV-AIDS hypothesis is, perhaps, the 
strongest argument in favor of seriously considering 
their critiques, not against it. 
Furthermore, credibility as an argument 
works both ways: if to question the trustworthiness 
of unorthodox scholars is vital, it is equally crucial to 
question the reliability of those supporting the HIV-
AIDS hypothesis. Readers who care to learn about 
HIV-AIDS’ history will encounter ethically-
questionable actions carried out by some of the most 
notable orthodox researchers, as well as ethical 
misconduct charges made against them (for an 
extensive treatment of these ethical and legal issues, 
backed by extensive official documentation, see 
Crewdson, 2002 [88]).  
If it is difficult to dismiss the unorthodox 
views due to the credibility of their sources, then, 
why aren’t orthodox scientists and practitioners 
more willing to rethink the hypothesis or, at the very 
least, test the unorthodox arguments in a scientific, 
open debate? Although there have been, in fact, 
several attempts to engage the orthodox community 
in dialogue, nearly all have been unsuccessful (for 
examples, see [15, 85, 88]). Most likely, reasons for 
denying the calls to re-examine the orthodox stance 
lie in the complex, synergistic dynamics within the 
scientific, medical, economic, and political systems or 
ideologies worldwide. Even brief speculation about 
these reasons would exceed the scope of this article, 
therefore I refer the reader, once again, to the 
sources referenced (in particular, see Epstein, 1996 
[89] and Bauer, 2007 [73]).  
Here I would argue, nonetheless, that the 
debate between orthodox and unorthodox scientists 
comprises much more than an intellectual pursuit or 
a scientific skirmish: it is a matter of life-and-death. It 
is a matter of justice. Millions of lives, worldwide, 
have been and will be significantly affected by an HIV 
or AIDS diagnosis. If we—the public health 
workforce—lose sight of the social justice 
implications and the magnitude of the effect, we lose 
“the very purpose of our mission” (3; 90, p. 690). 
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In particular, a pressing concern for public 
health is the move or push toward (a) HIV screening 
for “patients in all health-care settings” (with opt-out 
screening) (91) and (b) placing persons-at-risk (even 
if not yet infected with HIV), on retroviral medication 
as a form of prophylaxis (see discussion about PrEP, 
above) (92). If in 1986 the CDC recommended 
voluntary testing for people in high-risk groups, in 
2013 the U.S. Preventive Services Task Force “gave 
routine HIV screening of all adolescents and adults, 
ages 15 to 65, an ‘A’ rating” (93, p. 1). The recently 
approved Affordable Care ACT “requires or 
incentivizes new private health plans, Medicare, and 
Medicaid to provide preventive services rated ‘A’ or 
‘B’ at no cost to patients” (93, p. 1). Thus, routine 
screening of every adolescent and adult in all 
populations is, now, the goal (91, 94). 
If, to this goal we juxtapose the problems 
with the HIV tests, with the definition(s) of AIDS, and 
with the toxicity of the ARVs currently prescribed, we 
begin to understand the potential for harm inherent 
in them. Put blatantly: these recommendations can 
be harmful, or iatrogenic (95). 
 
Public health workforce: Our role 
What can the public health workforce do, 
given such potential for harm? As stated in the 
introduction, this paper represents a call to reflect 
upon our public health practice vis-à-vis HIV-AIDS. 
Reflecting upon and questioning the status quo 
constitute important dimensions of public health 
professionals’ competencies and practice. If the only 
hope the HIV-AIDS hypothesis can offer, thirty years 
later, is to provide highly toxic drugs to treat HIV 
infection and to prevent high-risk but healthy 
persons from becoming infected, health promoters 
have a professional duty to reflect on the available 
data and question the usefulness of the hypothesis. 
Only in doing so can public health professionals 
maintain their professional integrity, tend to public 
health’s roots in social justice, and contribute to 
developing knowledge using ethical methods.   
James Jones, in his book Bad Blood: The 
Tuskegee Syphilis Experiment (96), reminds us 
poignantly that not asking whether health 
professionals “should be doing” something, but 
continuing to do it uncritically, because “it can be 
done” was, ultimately, the mind-set sustaining the 
Tuskegee syphilis study for 40 years—unquestionably 
one of the worst cases of scientific misconduct in 
American history. The AIDS epidemic—if managed 
without questioning or without the dialogical process 
of action-reflection—may, with time, overshadow 
Tuskegee in the magnitude of its negative impact.   
Specifically, I propose the public health 
workforce can undertake such an action-reflection 
process by engaging in the following tasks:  
1) Learning about the history of the HIV/AIDS 
epidemic, of the problems surrounding the 
discovery of HIV, and about the development 
of drug therapies and PrEP. Publications 
recording this history abound in the 
professional and trade literatures, 
representing both mainstream and 
unorthodox view-points. To understand the 
forces shaping the HIV/AIDS epidemic we 
currently experience represents a crucial 
responsibility of a competent and ethics-
driven workforce.  
2) Conducting its own research to test 
alternative theories for the cause(s) of AIDS 
and/or to portray the inconsistencies and 
contradictions in the orthodox hypothesis. 
Qualitative inquiry, for instance, exploring 
unorthodox views and the practices of 
providers, patients, and scientists, might be a 
fruitful option for challenging prevailing 
assumptions.  
3) Fostering and mediating a debate among 
HIV-infected persons, scientists and health 
care providers, to critically assess current 
beliefs and practices. Public health 
professionals—who are well-informed about 
the orthodox and unorthodox perspectives’ 
strengths and weaknesses—could play an 
important role as facilitators in this much-
needed dialogue. 
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Although carrying out the tasks outlined 
above may represent a novelty for many public 
health professionals, for the scientists, practitioners 
and investigators who believe a viral hypothesis for 
AIDS is unproductive, none of this is new.  They have 
combed historical documents (or played a role in the 
history, themselves); they have amassed substantial 
amounts of data, and they have made numerous calls 
for debate. They have held to their beliefs, 
steadfastly, for the past 30 years. Twenty four years 
after the first article challenging HIV, Duesberg and 
colleagues, for instance, still claimed HIV is only a 
“passenger virus” (one “not sufficient and not 
necessary to cause a disease”) (62, p. 81). While not 
all unorthodox scholars agree with Duesberg, most 
still actively defend their critiques of the HIV-AIDS 
hypothesis and persist in their questioning. As we 
face the next decade with AIDS still rampant, then, it 
becomes vital that public health professionals attend 
to the debate and embark in a questioning of their 
own.  
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Table 1 – Credentials and Professional Experience of Select Critics of the HIV-AIDS Hypothesis 
NAME 
Alphabetical Order by Last 
Name 
 
CREDENTIALS 
 
Henry Bauer, Ph.D. Professor Emeritus of Chemistry & Science Studies 
Dean Emeritus of Arts & Sciences  
Virginia Polytechnic Institute & State University (Virginia Tech) 
 
James Chin, MD, MPH * Chief of Infectious Disease Section, California State Department of Health Services, Berkeley, 
California (1970s – 1987) 
Former Chief of Surveillance, Forecasting and Impact Assessment (SFI) Unit of the Global 
Programme on AIDS (GPA) of the World Health Organization 
Editor: APHA’s “Control of Communicable Diseases Manual” 
 
* Note: Chin agrees with the mainstream hypothesis that HIV is the cause of AIDS. His critique 
centers on the collection and interpretation of the epidemiological data for HIV/AIDS, in the US and 
world-wide. 
 
Ettiene de Harven, MD Emeritus Professor of Pathology: University of Toronto, Ontario.  
Specialized in electron microscopy at the “Institute du Cancer” in Paris 
Published first images of budding virus through EM (1960) 
Member: Sloan Kettering Institute, New York, NY in 1968. 
Former President: The Electron Microscopy Society of America (in 1976) 
Former President: Rethinking AIDS 
 
Peter Duesberg, Ph.D. Professor of Molecular and Cell Biology: The University of California, Berkeley 
Isolated the first cancer gene and mapped the genetic structure of retroviruses (1970) 
Member: National Academy of Sciences (since 1986) 
Outstanding Investigator Award – National Institutes of Health 1986 
 
Heinrich Kremer, MD Founder and Senior Consultant: Cell Symbiosis Therapy Academy® (based on his work on NO and its 
association with chronic inflammatory and degenerative disease). 
Collaborating Member: Study Group for Nutrition and Immunity (Bern, Germany) 
Extensive clinical work with youth drug addiction. 
 
Kary Mullis, Ph.D. Nobel Laureate – Chemistry – 1993 
Developed: Polymerase Chain Reaction 
Founder & Chief Scientific Advisor: Altermune  
 
David Rasnick, Ph.D. Biochemist with > 25 years of work with proteases and protease inhibitors. 
Former President: Rethinking AIDS: The Group for the Scientific Reappraisal of the HIV hypothesis 
Former President: International Coalition for Medical Justice 
 
